Balyasny Asset Management
INMB icon

Balyasny Asset Management’s INmune Bio INMB Stock Holding History

Balyasny Asset Management’s Portfolio INMB Stock Details INMB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-20,047
Closed -$236K – 2824
2024
Q1 		$236K Sell
20,047
-3,211
-14% -$38.8K ﹤0.01% 2347
2023
Q4 		$262K Buy
+23,258
New +$195K ﹤0.01% 2223

Other funds holding INMB

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CH
CVI Holdings Wilmington, Delaware $116M AUM 5.68% 1-Year Est. Return
PP
Praetorian PR Rincon, Puerto Rico $275M AUM 84.95% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
RJFSA
Raymond James Financial Services Advisors St. Petersburg, Florida $75.1B AUM 31.89% 1-Year Est. Return
RPAM
Rhenman & Partners Asset Management Stockholm, Sweden $810M AUM 30.2% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
MCM
MAI Capital Management Independence, Ohio $17.7B AUM 18.87% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

Balyasny Asset Management's INMB Position: Q2 2024 in Review

Balyasny Asset Management sold out of INmune Bio (INMB) in Q2 2024, closing a stake of 20,047 shares — an estimated $236K sold.

Balyasny Asset Management first reported a position in INMB in Q4 2023 and held it in 2 quarters. The position peaked at $262K in Q4 2023. 57 funds tracked by Wall St. Rank hold INMB as of Q2 2024.

  • Balyasny Asset Management reported no remaining INmune Bio position as of Q2 2024 after selling out during the quarter.
  • Balyasny Asset Management sold 20,047 INmune Bio shares in Q2 2024, an estimated $236K.
  • Balyasny Asset Management first reported a position in INmune Bio in Q4 2023 and held it in 2 quarters.
  • Balyasny Asset Management's INmune Bio position peaked at $262K in Q4 2023.
  • 57 funds tracked by Wall St. Rank held INmune Bio as of Q2 2024.

Based on Balyasny Asset Management's 13F filing for Q2 2024, filed 14 Aug 2024.